Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline.
Marker Therapeutics Inc (NASDAQ: MRKR) released the preliminary results of the first participant treated with MT-601, its multi-tumor associated antigen (multiTAA)-specific T cell product targeting 6 TAAs, in the Phase 1 multicenter
Gainers
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study in acromegaly.
Gainers
Yellow Corporation (NASDAQ: YELL) shares jumped 106% to $1.46. The trucking company ceased operations on Sunday, according to a Wall Street Journal report.